Vimarsana
Biggest News Aggregation in the World

Page 41 - Immunization Practices News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunization Practices. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunization Practices Today - Breaking & Trending Today

Analysis: Questions about vaccine pricing go unanswered - Vimarsana News

Analysis: Questions about vaccine pricing go unanswered

The world is entering a new era of vaccines. Following the success of COVID-19 mRNA shots, scientists have a far greater capacity to tailor shots to a virus’s structure, putting

Source: omaha.com
Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Vimarsana News

Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ®

Saint-Herblain (France), November 10, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the...

U.K. considers world's first use of meningitis vaccine to address gonorrhea - Vimarsana News

U.K. considers world's first use of meningitis vaccine to address gonorrhea

An expert panel that advises the U.K. on vaccine policy has recommended use of the meningitis B vaccine for certain populations.

Clinical Challenges: Navigating New RSV Protections for the Youngest Kids - Vimarsana News

Clinical Challenges: Navigating New RSV Protections for the Youngest Kids

Having options is worth the extra few minutes of conversation with families, physician says

Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records - Vimarsana News

Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records

Objectives To assess the effectiveness of live zoster vaccine during more than 10 years after vaccination; and to describe methods for ascertaining vaccine effectiveness in the context of waning. Design Real world cohort study using electronic health records. Setting Kaiser Permanente Northern California, an integrated healthcare delivery system in the US, 1 January 2007 to 31 December 2018. Population More than 1.5 million people aged 50 years and older followed for almost 9.4 million person years. Main outcome measure Vaccine effectiveness in preventing herpes zoster, postherpetic neuralgia,...

Source: bmj.com